Moderna CCO Arpa Garay departs; CEO & President to oversee commercial org

Moderna, Inc.

Arpa Garay no longer serves as Chief Commercial Officer effective Dec 8, 2023.
Commercial organization will be overseen by CEO Stéphane Bancel and President Stephen Hoge.
Garay to remain as employee through June 2024 in advisory capacity for transition.
Severance includes 12 months salary ($850,000), target bonus ($765,000), and COBRA.
Accelerated vesting of 15% of unvested time-based equity awards, plus 12-month option exercise window.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Arpa Garay

Chief Commercial Officer

MRNA · Moderna, Inc.

Effective: 2023-12-08
Filed: December 12, 2023, 6:59 PM ET

Arpa Garay, the Company’s Chief Commercial Officer, will be departing the Company, and that effective as of December 8, 2023, Ms. Garay will no longer serve in that role or as an executive officer of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Arpa Garay departed as Chief Commercial Officer at Moderna, Inc..

Action: departing
Role: Chief Commercial Officer

Exact text from the filing

Arpa Garay, the Company’s Chief Commercial Officer, will be departing the Company, and that effective as of December 8, 2023, Ms. Garay will no longer serve in that role or as an executive officer of the Company.

View on SEC.gov

Moderna, Inc. filing history →

Source: SEC EDGAR

accession 0001682852-23-000049

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.